Lutetium (177LU) tezuvotide tetraxetan
Highest phase reached
Phase 2
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Protein
- Drug name
- Lutetium (177LU) tezuvotide tetraxetan
- Molecular weight
- 1,573.48
- 177lu rhpsma 10 1
- 177lu-rhpsma-10.1
- Luteci0 (177lu) tezuvotida tetraxetan
- luteci0 177lu tezuvotida tetraxetan
- Lutecium (177lu) tezuvotide tetraxetan
- lutecium 177lu tezuvotide tetraxetan
- Lutetium (177lu) rhpsma-10.1
- Lutetium (177lu) tezuvotide tetraxetan
- lutetium 177lu rhpsma 10 1
- lutetium 177lu tezuvotide tetraxetan
- rhpsma 10 1 lutetium lu 177
- Rhpsma-10.1 lutetium lu-177
- ChEMBL ID
- CHEMBL6068058
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -tide; -xetan
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 98
- Molecular formula
- C60H92FLuN12O23Si
- Natural product
- No
Related records
Trials (138)
- [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake
- [177Lu]Lu-AKIR001 First-in-human Study
- [177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
- [177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer.
- [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application
- [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2
- 177Lu-AB-3PRGD2 in Patients With Integrin αVβ3 Positive Tumors
- 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer
- 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
- 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
- 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors
- 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
- 177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study
- 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
- 177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer
- 177Lu-HTK03170 in mCRPC With PSMA Positive Disease
- 177Lu-JH04 in Patients with FAP-Positive Tumors